Program Goals - PowerPoint PPT Presentation

slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Program Goals PowerPoint Presentation
Download Presentation
Program Goals

play fullscreen
1 / 60
Program Goals
228 Views
Download Presentation
philip-donovan
Download Presentation

Program Goals

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Program Goals

  2. Gastric and Esophageal Cancer in the United States, 2013

  3. Gastric Cancer Incidence: Geographic Differences

  4. Gastric Adenocarcinoma: Heterogeneous Diseases

  5. Gastric Cancer: Death Rates in the United States

  6. Subcardial Gastric Cancer Incidence: Trends Among Different Age Groups

  7. Gastric Adenocarcinoma: Heterogeneous Diseases

  8. Esophagogastric Adenocarcinomas: Pathologic Distinctions

  9. Pathogenesis of Esophagogastric Adenocarcinomas

  10. Gastric Cancer: Molecular Subtypes With Distinct Expression Profiles

  11. Gene Signature Validated in Primary Gastric Cancers: 2 Patient Cohorts

  12. Identifying Relevant Biologic Targets to Guide Therapeutic Development

  13. Significantly Mutated Genes in Whole-exome Sequencing Studies

  14. Exome Sequencing in GEJ and Esophageal Adenocarcinoma

  15. Candidate Biologic Pathways in Gastric Cancer

  16. Gastric Cancer: Single-Agent Chemotherapy

  17. Chemotherapy Regimens for Metastatic Esophagogastric Cancer

  18. HER/ErbB Family in Gastric Cancer

  19. ToGA: Phase 3 Trial of Trastuzumab in First-line Gastric/GEJ Cancer

  20. ToGA Primary End Point: OS

  21. ToGA Efficacy: OS by Subgroup Analysis

  22. HER2- Expression Frequency by Histologic Subtype

  23. T-DM1 Structure

  24. HER/ErbB Targeting in Gastric Cancer

  25. Rilotumumab in First-line Gastric/GEJ Cancer: Phase 2 Trial

  26. Rilotumumab Efficacy in ITT Population

  27. Rilotumumab Efficacy in MET-High Population

  28. Role of VEGF Pathway in Tumor Growth

  29. VEGF Expression Associated With Worse Survival in Gastric Cancer

  30. AVAGAST: Bevacizumab in First-line Gastric/GEJ Cancer - Phase 3 Trial

  31. AVAGAST Primary End Point: OS

  32. Role of VEGF Pathway in Tumor Growth

  33. Neovascularization and VEGFR2 Expression from Barrett’s to Esophageal Adenocarcinoma

  34. Anti-VEGFR2 MAb in a Gastric Cancer Animal Model

  35. REGARD: Ramucirumab Monotherapy in Second-line Gastric/GEJ Cancer, Phase 3 Trial

  36. REGARD: Efficacy Results

  37. RAINBOW: Ramucirumab in Second-line Gastric/GEJ Cancer, Phase 3 Trial

  38. Summary and Conclusions

  39. Summary and Conclusions (cont)

  40. Abbreviations

  41. Abbreviations (cont)

  42. Abbreviations (cont)